Post-marketing assessments of serious adverse drug reactions reported by the manufacturer to the FDA differ markedly with those from an independent pharmacovigilance program: Empirical findings based on bisphosphonate-associated osteonecrosis descriptions by the research on adverse events and reports project and the product manufacturer